Manish P Ponda1, Jan L Breslow. 1. Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York, NY 10065, USA. mponda@rockefeller.edu
Abstract
BACKGROUND: Vitamin D deficiency is common in the general population and even more prevalent in patients with chronic kidney disease (CKD). Low 25-hydroxyvitamin D [25(OH)D] levels have been associated with cardiovascular disease, though a definitive mechanistic link has not been established. Further, it is unclear if repleting vitamin D mitigates the excess risk observed in epidemiologic studies. Because vitamin D may regulate innate immunity and gut epithelial differentiation, we hypothesized that oral cholecalciferol (D3) would result in decreased blood endotoxin activity, a potential risk factor for cardiovascular disease. STUDY DESIGN, SETTING & PARTICIPANTS, INTERVENTION: We studied 12 stable outpatients with CKD stage 3 and 25(OH)D deficiency, who received D3 30,000 units weekly for 8 weeks. The primary endpoint was the change in blood endotoxin activity. RESULTS: Baseline endotoxin activity correlated with 25(OH)D levels (r = -0.60, p = 0.04). Endotoxin activity decreased by 25% from baseline (p = 0.03). Despite the decrease in endotoxin activity, there was no change in intestinal permeability. CONCLUSION: The results of this study suggest that vitamin D repletion therapy may have an effect on endotoxin activity in early CKD. Further intervention studies using vitamin D in the CKD population are required.
BACKGROUND:Vitamin D deficiency is common in the general population and even more prevalent in patients with chronic kidney disease (CKD). Low 25-hydroxyvitamin D [25(OH)D] levels have been associated with cardiovascular disease, though a definitive mechanistic link has not been established. Further, it is unclear if repleting vitamin D mitigates the excess risk observed in epidemiologic studies. Because vitamin D may regulate innate immunity and gut epithelial differentiation, we hypothesized that oral cholecalciferol (D3) would result in decreased blood endotoxin activity, a potential risk factor for cardiovascular disease. STUDY DESIGN, SETTING & PARTICIPANTS, INTERVENTION: We studied 12 stable outpatients with CKD stage 3 and 25(OH)D deficiency, who received D3 30,000 units weekly for 8 weeks. The primary endpoint was the change in blood endotoxin activity. RESULTS: Baseline endotoxin activity correlated with 25(OH)D levels (r = -0.60, p = 0.04). Endotoxin activity decreased by 25% from baseline (p = 0.03). Despite the decrease in endotoxin activity, there was no change in intestinal permeability. CONCLUSION: The results of this study suggest that vitamin D repletion therapy may have an effect on endotoxin activity in early CKD. Further intervention studies using vitamin D in the CKD population are required.
Authors: Peter R Holt; Nadir Arber; Balazs Halmos; Kenneth Forde; Harry Kissileff; Katherine A McGlynn; Steven F Moss; N Kurihara; K Fan; Kunhua Yang; Martin Lipkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-01 Impact factor: 4.254
Authors: D Zehnder; R Bland; M C Williams; R W McNinch; A J Howie; P M Stewart; M Hewison Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: C J Wiedermann; S Kiechl; S Dunzendorfer; P Schratzberger; G Egger; F Oberhollenzer; J Willeit Journal: J Am Coll Cardiol Date: 1999-12 Impact factor: 24.094
Authors: Manish P Ponda; Kathleen Dowd; Dennis Finkielstein; Peter R Holt; Jan L Breslow Journal: Arterioscler Thromb Vasc Biol Date: 2012-09-04 Impact factor: 8.311
Authors: John C Marshall; Paul M Walker; Debra M Foster; David Harris; Melanie Ribeiro; Jeff Paice; Alexander D Romaschin; Anastasia N Derzko Journal: Crit Care Date: 2002-05-02 Impact factor: 9.097
Authors: Andrea Galassi; Antonio Bellasi; Sara Auricchio; Sergio Papagni; Mario Cozzolino Journal: Biomed Res Int Date: 2013-08-07 Impact factor: 3.411
Authors: Rodolphe Anty; M Tonohouan; P Ferrari-Panaia; T Piche; A Pariente; Q M Anstee; P Gual; A Tran Journal: Clin Transl Gastroenterol Date: 2014-05-29 Impact factor: 4.488